In the News

Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial

Gateway for Cancer Research accelerates practice-changing clinical trials to cancer research by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.

Speed and Rigor Are Not in Conflict

Garo Armen argues FDA Operation TrialBlazer should put patients first by speeding evidence-based access to cancer treatments without lowering standards.

Global Health Dialogues with Princess Dina and Dr. Garo Armen

Garo H. Armen, PhD, Chairman and Chief Executive Officer, Agenus and Princess Dina explore the promise and limits of immunotherapy.

The Old System Failed Patients. Change Must Go Further and Faster

Garo H. Armen, PhD, Chairman and Chief Executive Officer, Agenus provides perspectives on further changes needed to support innovations for patients

Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito

An in-depth profile of Dr. Nicholas DeVito on why immunotherapy should come first—exploring Bot/Bal, trial design, and how sequencing can drive durable cancer control.

Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver metastases.

Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200